Miruvor
Sign up
The short answer

What studies of low-dose naltrexone found

39papers on low-dose naltrexone
397people in 5 studies testing low-dose naltrexone alone
1randomised trial, the strongest kind of study

At a glance, by condition

Long COVID: D Little or no difference

Based on the strongest evidence, the placebo trial (moderate certainty), for fatigue.

14 outcomes rated · see each below

ME/CFS: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 4 findings, all C.

4 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, studies found little or no difference with LDN. For ME/CFS, LDN might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 39 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. LDN · ME/CFS is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. LDN · Long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Fatigue4 studies · 172 people took low-dose naltrexone Mixed results C
Low certainty

Why this grade: Mixed results, low certainty, from randomised trials: the trial was designed to detect a 4.7-point difference in FSS; its 95% CI (-4.18 to 2.67) excludes that: a moderate benefit is unlikely, a small one can't be ruled out; effect size 0.08 (very small); inconsistency: 2 studies without a placebo group found improvement.

The placebo trial160 randomised · 137 analysed · at 16 weeks · starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4

No clear difference in fatigue.

Low-dose naltrexone probably makes little or no difference to fatigue in long COVID. Little or no difference · moderate certainty D

  • The trial was designed to detect a 4.7-point difference in FSS; its 95% CI (-4.18 to 2.67) excludes that: a moderate benefit is unlikely, a small one can't be ruled out
  • Effect size 0.08 (very small)

How big was the difference?

0.08, very small. The effect size compares low-dose naltrexone with placebo.

Compared with another group, not randomised108 in the study · at least 1 month after starting treatment · 1.5–4.5 mg daily

No clear difference in fatigue.

The evidence is very uncertain about the effect of low-dose naltrexone on fatigue in long COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
  • Rests mainly on values read from a figure
  • About 82% with low-dose naltrexone, against about 82% with physical therapy (the reference); about 90% with duloxetine; about 80% with amitriptyline. Read from Figure 2 (approximate); the figure marks no test of this comparison

Studies with no comparison group2 studies · 95 people with results

Fatigue improved.

The evidence is very uncertain about the effect of low-dose naltrexone on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Only people who finished were analysed
See the 4 studies
  1. Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial (2026) preprint

    People in the study
    160 randomised · 137 analysed
    Dose
    starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4
    Outcome
    FSS Fatigue Severity Scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Low-dose Naltrexone Improves post-COVID-19 condition Symptoms. (2024)

    People in the study
    108 in the study
    Dose
    1.5–4.5 mg daily
    Outcome
    Fatigue (read from Figure 2)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, Charlson Comorbidity Index score and prior COVID-19 hospitalization Adjusted for age, Charlson Comorbidity Index score and prior COVID-19 hospitalization.
    Selection of participants
    Moderate. comparison group: non-randomised treatment selection by age, medication interactions, presenting symptoms, and prior treatment failure older, sicker patients were treated with duloxetine and physical therapy
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: incomplete data for the analysis of inflammatory markers; Low-dose naltrexone; 16; Amitriptyline; 14; Duloxetine; 13; Physical therapy; 8; Changes in biomarkers by treatments.; Low-dose naltrexone; Amitriptyline; Duloxetine; Physical therapy; n; 16; 14; 13; 8 we had incomplete data for the analysis of inflammatory markers
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. (2023)

    People in the study
    59 in the study
    Dose
    0.5 mg daily to 6.0 mg daily
    Outcome
    fatigue
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  4. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. (2022)

    People in the study
    52 in the study · 38 started · 36 with outcome data
    Dose
    1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg
    Outcome
    In the past 4 weeks do you have a lot of energy? (1–6)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Sleep3 studies · 172 people took low-dose naltrexone Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from randomised trials: one trial of 137 people found no clear difference; a small benefit can't be ruled out; inconsistency: 2 studies without a placebo group found improvement.

The placebo trial160 randomised · 137 analysed · at 16 weeks · starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4

No clear difference in sleep.

Low-dose naltrexone may make little or no difference to sleep in long COVID. Little or no difference · low certainty D

  • One trial of 137 people found no clear difference; a small benefit can't be ruled out

Studies with no comparison group2 studies · 95 people with results

Sleep improved.

The evidence is very uncertain about the effect of low-dose naltrexone on sleep in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Only people who finished were analysed
See the 3 studies
  1. Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial (2026) preprint

    People in the study
    160 randomised · 137 analysed
    Dose
    starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4
    Outcome
    sleep
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. (2023)

    People in the study
    59 in the study
    Dose
    0.5 mg daily to 6.0 mg daily
    Outcome
    unrefreshing sleep
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  3. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. (2022)

    People in the study
    52 in the study · 38 started · 36 with outcome data
    Dose
    1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg
    Outcome
    Have you trouble staying or falling asleep(1–4)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Post-exertional malaise2 studies · 136 people took low-dose naltrexone Little or no difference D
Low certainty

Why this grade: Little or no difference, low certainty, from randomised trials: one trial of 137 people found no clear difference; a small benefit can't be ruled out.

The placebo trial160 randomised · 137 analysed · at 16 weeks · starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4

No clear difference in post-exertional malaise.

Low-dose naltrexone may make little or no difference to post-exertional malaise in long COVID. Little or no difference · low certainty D

  • One trial of 137 people found no clear difference; a small benefit can't be ruled out

Studies with no comparison group59 in the study · The median number of days on LDN was 143 days [IQR 77–255]. · 0.5 mg daily to 6.0 mg daily

Post-exertional malaise improved.

The evidence is very uncertain about the effect of low-dose naltrexone on post-exertional malaise in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
See the 2 studies
  1. Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial (2026) preprint

    People in the study
    160 randomised · 137 analysed
    Dose
    starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4
    Outcome
    post-exertional malaise (PEM) post-exertional malaise
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. (2023)

    People in the study
    59 in the study
    Dose
    0.5 mg daily to 6.0 mg daily
    Outcome
    post-exertional malaise
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)3 studies · 113 people took low-dose naltrexone Little or no difference D
Low certainty

Why this grade: Little or no difference, low certainty, from randomised trials: one trial of 137 people found no clear difference; a small benefit can't be ruled out.

The placebo trial160 randomised · 137 analysed · at 16 weeks · starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4

No clear difference in cognition (brain fog).

Low-dose naltrexone may make little or no difference to cognition (brain fog) in long COVID. Little or no difference · low certainty D

  • One trial of 137 people found no clear difference; a small benefit can't be ruled out

Compared with another group, not randomised108 in the study · at least 1 month after starting treatment · 1.5–4.5 mg daily

No clear difference in cognition (brain fog).

The evidence is very uncertain about the effect of low-dose naltrexone on cognition (brain fog) in long COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
  • Rests mainly on values read from a figure
  • About 25% with low-dose naltrexone, against about 30% with physical therapy (the reference); about 10% with duloxetine; about 4% with amitriptyline. Read from Figure 2 (approximate); the figure marks no test of this comparison

Studies with no comparison group52 in the study · 38 started · 36 with outcome data · two-three month period · 1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg

Cognition (brain fog) improved.

The evidence is very uncertain about the effect of low-dose naltrexone on cognition (brain fog) in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (36 in all)
  • Only people who finished were analysed
See the 3 studies
  1. Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial (2026) preprint

    People in the study
    160 randomised · 137 analysed
    Dose
    starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4
    Outcome
    cognitive impairment
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Low-dose Naltrexone Improves post-COVID-19 condition Symptoms. (2024)

    People in the study
    108 in the study
    Dose
    1.5–4.5 mg daily
    Outcome
    Brain fog (read from Figure 2)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, Charlson Comorbidity Index score and prior COVID-19 hospitalization Adjusted for age, Charlson Comorbidity Index score and prior COVID-19 hospitalization.
    Selection of participants
    Moderate. comparison group: non-randomised treatment selection by age, medication interactions, presenting symptoms, and prior treatment failure older, sicker patients were treated with duloxetine and physical therapy
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: incomplete data for the analysis of inflammatory markers; Low-dose naltrexone; 16; Amitriptyline; 14; Duloxetine; 13; Physical therapy; 8; Changes in biomarkers by treatments.; Low-dose naltrexone; Amitriptyline; Duloxetine; Physical therapy; n; 16; 14; 13; 8 we had incomplete data for the analysis of inflammatory markers
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. (2022)

    People in the study
    52 in the study · 38 started · 36 with outcome data
    Dose
    1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg
    Outcome
    In the past 4 weeks rate your level of concentration(1–5)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Pain3 studies · 113 people took low-dose naltrexone Little or no difference D
Low certainty

Why this grade: Little or no difference, low certainty, from randomised trials: one trial of 137 people found no clear difference; a small benefit can't be ruled out; effect size 0.01 (very small).

The placebo trial160 randomised · 137 analysed · at 16 weeks · starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4

No clear difference in pain.

Low-dose naltrexone may make little or no difference to pain in long COVID. Little or no difference · low certainty D

  • One trial of 137 people found no clear difference; a small benefit can't be ruled out
  • Effect size 0.01 (very small)

How big was the difference?

0.01, very small. The effect size compares low-dose naltrexone with placebo.

Compared with another group, not randomised108 in the study · at least 1 month after starting treatment · 1.5–4.5 mg daily

No clear difference in pain.

The evidence is very uncertain about the effect of low-dose naltrexone on pain in long COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
  • Rests mainly on values read from a figure
  • About 75% with low-dose naltrexone, against about 18% with physical therapy (the reference); about 8% with duloxetine; about 3% with amitriptyline. Read from Figure 2 (approximate); the figure marks no test of this comparison

Studies with no comparison group52 in the study · 38 started · 36 with outcome data · two-three month period · 1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg

Pain improved.

The evidence is very uncertain about the effect of low-dose naltrexone on pain in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (36 in all)
  • Only people who finished were analysed
See the 3 studies
  1. Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial (2026) preprint

    People in the study
    160 randomised · 137 analysed
    Dose
    starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4
    Outcome
    Pain VAS pain visual analogue scale (VAS)
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Low-dose Naltrexone Improves post-COVID-19 condition Symptoms. (2024)

    People in the study
    108 in the study
    Dose
    1.5–4.5 mg daily
    Outcome
    Pain (read from Figure 2)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, Charlson Comorbidity Index score and prior COVID-19 hospitalization Adjusted for age, Charlson Comorbidity Index score and prior COVID-19 hospitalization.
    Selection of participants
    Moderate. comparison group: non-randomised treatment selection by age, medication interactions, presenting symptoms, and prior treatment failure older, sicker patients were treated with duloxetine and physical therapy
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: incomplete data for the analysis of inflammatory markers; Low-dose naltrexone; 16; Amitriptyline; 14; Duloxetine; 13; Physical therapy; 8; Changes in biomarkers by treatments.; Low-dose naltrexone; Amitriptyline; Duloxetine; Physical therapy; n; 16; 14; 13; 8 we had incomplete data for the analysis of inflammatory markers
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. (2022)

    People in the study
    52 in the study · 38 started · 36 with outcome data
    Dose
    1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg
    Outcome
    In the past 4 weeks rate you pain/discomfort(1–5)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Anxiety2 studies · 113 people took low-dose naltrexone Little or no difference D
Low certainty

Why this grade: Little or no difference, low certainty, from randomised trials: one trial of 137 people found no clear difference; a small benefit can't be ruled out.

The placebo trial160 randomised · 137 analysed · at 16 weeks · starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4

No clear difference in anxiety.

Low-dose naltrexone may make little or no difference to anxiety in long COVID. Little or no difference · low certainty D

  • One trial of 137 people found no clear difference; a small benefit can't be ruled out

Studies with no comparison group52 in the study · 38 started · 36 with outcome data · two-three month period · 1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg

No clear change in anxiety.

The evidence is very uncertain about the effect of low-dose naltrexone on anxiety in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (36 in all)
  • Only people who finished were analysed
See the 2 studies
  1. Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial (2026) preprint

    People in the study
    160 randomised · 137 analysed
    Dose
    starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4
    Outcome
    General Anxiety Disorder-7
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. (2022)

    People in the study
    52 in the study · 38 started · 36 with outcome data
    Dose
    1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg
    Outcome
    Anxiety
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Autonomic symptoms2 studies · 113 people took low-dose naltrexone Little or no difference D
Low certainty

Why this grade: Little or no difference, low certainty, from randomised trials: one trial of 137 people found no clear difference; a small benefit can't be ruled out.

The placebo trial160 randomised · 137 analysed · at 16 weeks · starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4

No clear difference in autonomic symptoms.

Low-dose naltrexone may make little or no difference to autonomic symptoms in long COVID. Little or no difference · low certainty D

  • One trial of 137 people found no clear difference; a small benefit can't be ruled out

Studies with no comparison group52 in the study · 38 started · 36 with outcome data · two-three month period · 1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg

No clear change in autonomic symptoms.

The evidence is very uncertain about the effect of low-dose naltrexone on autonomic symptoms in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (36 in all)
  • Only people who finished were analysed
See the 2 studies
  1. Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial (2026) preprint

    People in the study
    160 randomised · 137 analysed
    Dose
    starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4
    Outcome
    orthostatic intolerance
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. (2022)

    People in the study
    52 in the study · 38 started · 36 with outcome data
    Dose
    1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg
    Outcome
    Palpitations
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Depression1 study · 77 people took low-dose naltrexone Little or no difference D
Low certainty

Why this grade: Little or no difference, low certainty, from randomised trials: one trial of 137 people found no clear difference; a small benefit can't be ruled out.

The placebo trial160 randomised · 137 analysed · at 16 weeks · starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4

No clear difference in depression.

Low-dose naltrexone may make little or no difference to depression in long COVID. Little or no difference · low certainty D

  • One trial of 137 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial (2026) preprint

    People in the study
    160 randomised · 137 analysed
    Dose
    starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4
    Outcome
    Patient Health Questionnaire-9
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
Breathlessness2 studies · 36 people took low-dose naltrexone Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance; rests mainly on values read from a figure; about 25% with low-dose naltrexone, against about 100% with physical therapy (the reference); about 40% with duloxetine; about 8% with amitriptyline. Read from Figure 2 (approximate); the figure marks no test of this comparison.

Compared with another group, not randomised108 in the study · at least 1 month after starting treatment · 1.5–4.5 mg daily

No clear difference in breathlessness.

The evidence is very uncertain about the effect of low-dose naltrexone on breathlessness in long COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
  • Rests mainly on values read from a figure
  • About 25% with low-dose naltrexone, against about 100% with physical therapy (the reference); about 40% with duloxetine; about 8% with amitriptyline. Read from Figure 2 (approximate); the figure marks no test of this comparison

Studies with no comparison group52 in the study · 38 started · 36 with outcome data · two-three month period · 1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg

No clear change in breathlessness.

The evidence is very uncertain about the effect of low-dose naltrexone on breathlessness in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (36 in all)
  • Only people who finished were analysed
See the 2 studies
  1. Low-dose Naltrexone Improves post-COVID-19 condition Symptoms. (2024)

    People in the study
    108 in the study
    Dose
    1.5–4.5 mg daily
    Outcome
    Dyspnea (read from Figure 2)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, Charlson Comorbidity Index score and prior COVID-19 hospitalization Adjusted for age, Charlson Comorbidity Index score and prior COVID-19 hospitalization.
    Selection of participants
    Moderate. comparison group: non-randomised treatment selection by age, medication interactions, presenting symptoms, and prior treatment failure older, sicker patients were treated with duloxetine and physical therapy
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: incomplete data for the analysis of inflammatory markers; Low-dose naltrexone; 16; Amitriptyline; 14; Duloxetine; 13; Physical therapy; 8; Changes in biomarkers by treatments.; Low-dose naltrexone; Amitriptyline; Duloxetine; Physical therapy; n; 16; 14; 13; 8 we had incomplete data for the analysis of inflammatory markers
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. (2022)

    People in the study
    52 in the study · 38 started · 36 with outcome data
    Dose
    1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg
    Outcome
    Shortness of breath
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Low mood or anxiety1 study · 36 people took low-dose naltrexone Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (36 in all); only people who finished were analysed.

Studies with no comparison group52 in the study · 38 started · 36 with outcome data · two-three month period · 1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg

No clear change in low mood or anxiety.

The evidence is very uncertain about the effect of low-dose naltrexone on low mood or anxiety in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (36 in all)
  • Only people who finished were analysed
See the 1 study
  1. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. (2022)

    People in the study
    52 in the study · 38 started · 36 with outcome data
    Dose
    1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg
    Outcome
    In the past 4 weeks rate your overall mood(1–5)
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Smell and taste loss1 study · 36 people took low-dose naltrexone Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (36 in all); only people who finished were analysed.

Studies with no comparison group52 in the study · 38 started · 36 with outcome data · two-three month period · 1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg

No clear change in smell and taste loss.

The evidence is very uncertain about the effect of low-dose naltrexone on smell and taste loss in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (36 in all)
  • Only people who finished were analysed
See the 1 study
  1. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. (2022)

    People in the study
    52 in the study · 38 started · 36 with outcome data
    Dose
    1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg
    Outcome
    Anosmia/dysgeusia
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms4 studies · 196 people took low-dose naltrexone Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from randomised trials: one trial of 137 people found no clear difference; a small benefit can't be ruled out; effect size 0.11 (very small); inconsistency: 3 studies without a placebo group found improvement.

The placebo trial160 randomised · 137 analysed · at 16 weeks · starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4

No clear difference in overall symptoms.

Low-dose naltrexone may make little or no difference to overall symptoms in long COVID. Little or no difference · low certainty D

  • One trial of 137 people found no clear difference; a small benefit can't be ruled out
  • Effect size 0.11 (very small)

How big was the difference?

0.11, very small. The effect size compares low-dose naltrexone with placebo.

Compared with another group, not randomised108 in the study · at least 1 month after starting treatment · 1.5–4.5 mg daily

Overall symptoms improved more than in the comparison group.

The evidence is very uncertain about the effect of low-dose naltrexone on overall symptoms in long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • 67% improved with low-dose naltrexone vs 41% with physical therapy

Studies with no comparison group2 studies · 95 people with results

Overall symptoms improved.

The evidence is very uncertain about the effect of low-dose naltrexone on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Only people who finished were analysed
See the 4 studies
  1. Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial (2026) preprint

    People in the study
    160 randomised · 137 analysed
    Dose
    starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4
    Outcome
    PQSymp-12 Patient Phenotyping Questionnaire Short Form, PQSymp-12
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Low-dose Naltrexone Improves post-COVID-19 condition Symptoms. (2024)

    People in the study
    108 in the study
    Dose
    1.5–4.5 mg daily
    Outcome
    adjusted relative hazard of improvement
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, Charlson Comorbidity Index score and prior COVID-19 hospitalization Adjusted for age, Charlson Comorbidity Index score and prior COVID-19 hospitalization.
    Selection of participants
    Moderate. comparison group: non-randomised treatment selection by age, medication interactions, presenting symptoms, and prior treatment failure older, sicker patients were treated with duloxetine and physical therapy
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: incomplete data for the analysis of inflammatory markers; Low-dose naltrexone; 16; Amitriptyline; 14; Duloxetine; 13; Physical therapy; 8; Changes in biomarkers by treatments.; Low-dose naltrexone; Amitriptyline; Duloxetine; Physical therapy; n; 16; 14; 13; 8 we had incomplete data for the analysis of inflammatory markers
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  3. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. (2022)

    People in the study
    52 in the study · 38 started · 36 with outcome data
    Dose
    1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg
    Outcome
    I feel I have recovered from COVID-19 (1–5)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  4. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. (2023)

    People in the study
    59 in the study
    Dose
    0.5 mg daily to 6.0 mg daily
    Outcome
    total number of symptoms
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily functioning3 studies · 172 people took low-dose naltrexone Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from randomised trials: one trial of 137 people found no clear difference; a small benefit can't be ruled out; inconsistency: 2 studies without a placebo group found improvement.

The placebo trial160 randomised · 137 analysed · at 16 weeks · starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4

No clear difference in daily functioning.

Low-dose naltrexone may make little or no difference to daily functioning in long COVID. Little or no difference · low certainty D

  • One trial of 137 people found no clear difference; a small benefit can't be ruled out

Studies with no comparison group2 studies · 95 people with results

Daily functioning improved.

The evidence is very uncertain about the effect of low-dose naltrexone on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Only people who finished were analysed
See the 3 studies
  1. Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial (2026) preprint

    People in the study
    160 randomised · 137 analysed
    Dose
    starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4
    Outcome
    post-COVID-19 Functional Status Scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. (2022)

    People in the study
    52 in the study · 38 started · 36 with outcome data
    Dose
    1 mg once daily for one month, the dose was increased by 1 mg monthly to a maximum of 3 mg, once daily; increased by 1 mg monthly to a maximum of 3 mg
    Outcome
    Does you health now limit you in you in daily activities? How much (1–3)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  3. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. (2023)

    People in the study
    59 in the study
    Dose
    0.5 mg daily to 6.0 mg daily
    Outcome
    functional status scale (FSS) Post COVID-19 Functional Status Scale (FSS) modified from Klok et al.
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Quality of life1 study · 77 people took low-dose naltrexone Little or no difference D
Low certainty

Why this grade: Little or no difference, low certainty, from randomised trials: one trial of 137 people found no clear difference; a small benefit can't be ruled out; effect size 0.10 (very small).

The placebo trial160 randomised · 137 analysed · at 16 weeks · starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4

No clear difference in quality of life.

Low-dose naltrexone may make little or no difference to quality of life in long COVID. Little or no difference · low certainty D

  • One trial of 137 people found no clear difference; a small benefit can't be ruled out
  • Effect size 0.10 (very small)

How big was the difference?

0.1, very small. The effect size compares low-dose naltrexone with placebo.

See the 1 study
  1. Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial (2026) preprint

    People in the study
    160 randomised · 137 analysed
    Dose
    starting at 1.0 mg daily, increasing to 4.5 mg as tolerated, daily; up-titrated weekly to a maximum of 4.5 mg daily by week 4
    Outcome
    EQ-5D-5L utility EQ-5D-5L
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low

ME/CFS

Symptoms

Cognition (brain fog)1 study · 201 people took low-dose naltrexone Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.

Studies with no comparison group218 in the study · 201 with outcome data · average follow-up period was 1.7 years (range 0.1–6.8 years); quote: 'The average follow-up period was 1.7 years (range 0.1–6.8 years).' · 3.0 – 4.5 mg/day, morning dose of 1.5 mg for one week, then daily dose of 3.0 mg (1.5 mg twice daily); after six weeks allowed to increase to 4.5 mg

Cognition (brain fog) improved.

The evidence is very uncertain about the effect of low-dose naltrexone on cognition (brain fog) in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
See the 1 study
  1. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) (2019)

    People in the study
    218 in the study · 201 with outcome data
    Dose
    3.0 – 4.5 mg/day, morning dose of 1.5 mg for one week, then daily dose of 3.0 mg (1.5 mg twice daily); after six weeks allowed to increase to 4.5 mg
    Outcome
    Improved cognition
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Pain1 study · 201 people took low-dose naltrexone Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.

Studies with no comparison group218 in the study · 201 with outcome data · average follow-up period was 1.7 years (range 0.1–6.8 years); quote: 'The average follow-up period was 1.7 years (range 0.1–6.8 years).' · 3.0 – 4.5 mg/day, morning dose of 1.5 mg for one week, then daily dose of 3.0 mg (1.5 mg twice daily); after six weeks allowed to increase to 4.5 mg

Pain improved.

The evidence is very uncertain about the effect of low-dose naltrexone on pain in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance

Combination: Spironolactone + Colchicine + Low-dose naltrexone + Multivitamins (Centrum)

White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome (2024): SF-36 – Body pain, no clear difference.

Shown, not counted: low-dose naltrexone was given together with other treatments.

See the 1 study
  1. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) (2019)

    People in the study
    218 in the study · 201 with outcome data
    Dose
    3.0 – 4.5 mg/day, morning dose of 1.5 mg for one week, then daily dose of 3.0 mg (1.5 mg twice daily); after six weeks allowed to increase to 4.5 mg
    Outcome
    Pain relief
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning1 study · 201 people took low-dose naltrexone Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.

Studies with no comparison group218 in the study · 201 with outcome data · average follow-up period was 1.7 years (range 0.1–6.8 years); quote: 'The average follow-up period was 1.7 years (range 0.1–6.8 years).' · 3.0 – 4.5 mg/day, morning dose of 1.5 mg for one week, then daily dose of 3.0 mg (1.5 mg twice daily); after six weeks allowed to increase to 4.5 mg

Daily functioning improved.

The evidence is very uncertain about the effect of low-dose naltrexone on daily functioning in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance

Combination: Spironolactone + Colchicine + Low-dose naltrexone + Multivitamins (Centrum)

White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome (2024): SF-36 – Physical functioning, no clear difference.

Shown, not counted: low-dose naltrexone was given together with other treatments.

See the 1 study
  1. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) (2019)

    People in the study
    218 in the study · 201 with outcome data
    Dose
    3.0 – 4.5 mg/day, morning dose of 1.5 mg for one week, then daily dose of 3.0 mg (1.5 mg twice daily); after six weeks allowed to increase to 4.5 mg
    Outcome
    Improved physical performance
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 201 people took low-dose naltrexone Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.

Studies with no comparison group218 in the study · 201 with outcome data · average follow-up period was 1.7 years (range 0.1–6.8 years); quote: 'The average follow-up period was 1.7 years (range 0.1–6.8 years).' · 3.0 – 4.5 mg/day, morning dose of 1.5 mg for one week, then daily dose of 3.0 mg (1.5 mg twice daily); after six weeks allowed to increase to 4.5 mg

Overall symptoms improved.

The evidence is very uncertain about the effect of low-dose naltrexone on overall symptoms in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance

Combination: Spironolactone + Colchicine + Low-dose naltrexone + Multivitamins (Centrum)

White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome (2024): SF-36 – General health, no clear difference.

Shown, not counted: low-dose naltrexone was given together with other treatments.

See the 1 study
  1. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) (2019)

    People in the study
    218 in the study · 201 with outcome data
    Dose
    3.0 – 4.5 mg/day, morning dose of 1.5 mg for one week, then daily dose of 3.0 mg (1.5 mg twice daily); after six weeks allowed to increase to 4.5 mg
    Outcome
    Any treatment response to LDN
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Studies of combinations

Outcomes that only studies of low-dose naltrexone given together with other treatments looked at. Shown, not graded: they can’t tell what low-dose naltrexone did alone.

Low mood or anxiety ME/CFS

Combination: Spironolactone + Colchicine + Low-dose naltrexone + Multivitamins (Centrum)

White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome (2024): Hospital Anxiety and Depression Scale (HADS) – Depression, better.

Shown, not counted: low-dose naltrexone was given together with other treatments.

Fatigue ME/CFS

Combination: Spironolactone + Colchicine + Low-dose naltrexone + Multivitamins (Centrum)

White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome (2024): SF-36 – Vitality, no clear difference.

Shown, not counted: low-dose naltrexone was given together with other treatments.

Side effects

In the placebo trial, as the paper reports them.

Had at least one side effect
LDN79% had at least one
Placebo84% had at least one

As printed: Participants with ≥ 1 AE 64 (79.0%) 66 (83.5%)

6% vs 4%

had a severe side effect, LDN vs placebo

2 vs 0

had a serious one, LDN vs placebo

0 vs 0

deaths, LDN vs placebo

Stopping because of side effects2 studies
Side effects studies reported8 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Fatigue3 studies
Headache3 studies
Vivid dreams or nightmares3 studies
Worse symptoms or a flare3 studies
Dizziness2 studies
Nausea or stomach upset2 studies
Trouble sleeping2 studies
Anxiety or irritability1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    1 to 4 mg at the start in most studies

  2. 2Raise

    Raised step by step in 8 of 10 studies

  3. 3Top dose

    Most often 4.5 mg (5 of 10 studies)

Doses across 10 studies

0.5 to 6 mg. One study of 3 people went up to 12 mg.

Each study’s dose, as printed

Systematic reviews

Reviews pool earlier studies. Each shows when it was published and how far its search went.

All papers

  1. Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial2026 · placebo trial · 160 randomised · 137 analysed · preprint
    Summary

    Researchers tested low-dose naltrexone (LDN) in adults with post-COVID fatigue syndrome (PCFS) in British Columbia and Ontario, Canada. The randomized, double-blind, placebo-controlled trial enrolled 160 participants: 81 assigned to LDN and 79 to placebo. Participants received oral LDN starting at 1.0 mg daily and increasing to 4.5 mg as tolerated, or placebo, for 16 weeks. The primary outcome was fatigue severity on the Fatigue Severity Scale (FSS) at 16 weeks; secondary outcomes included pain VAS, PQSymp-12, daily step count, and EQ-5D-5L utility. At 16 weeks, there was no difference in FSS between groups (adjusted mean difference -0.76, 95% CI -4.18 to 2.67; P=0.66). There were also no differences in pain VAS (0.03, 95% CI -0.50 to 0.57), PQSymp-12 (-0.70, 95% CI -2.57 to 1.17), daily step count (-5, 95% CI -720 to 729), or EQ-5D-5L utility (0.02, 95% CI -0.03 to 0.06). FSS scores declined in both groups from baseline to 16 weeks. Clinical improvement was 29/66 (44%) with LDN and 29/71 (41%) with placebo; worsening was 6/66 (9%) and 3/71 (4%). Total adverse events were 405 with LDN and 300 with placebo; 64 (79.0%) and 66 (83.5%) participants had at least one adverse event. Grade 3-4 adverse events occurred in 5 (6.2%) and 3 (3.8%); SAEs in 2 (2.5%) and 0 (0.0%). Two LDN participants had severe adverse events and treatment was stopped.

  2. Low-dose Naltrexone Improves post-COVID-19 condition Symptoms.2024 · compared with another group · 108 in the study
    Summary

    Researchers conducted a retrospective cohort study comparing four treatments in 108 patients with post–COVID-19 condition at the Miami Veterans Affairs post–COVID-19 clinic between 2021 and January 2023. Patients received low-dose naltrexone 1.5–4.5 mg daily (n = 24), amitriptyline 10–20 mg daily (n = 41), duloxetine 20–120 mg daily (n = 17), or physical therapy (n = 26), with follow-up at least 1 month after starting treatment. Sixty-seven percent reported improvement in the low-dose naltrexone group compared with 61% taking amitriptyline and 41% receiving physical therapy alone; patients taking duloxetine only reported improvement in 35%. The relative hazard of improvement for those taking low-dose naltrexone was 5.04 (95% CI, 1.22–20.77; P = 0.02) compared with physical therapy alone, while amitriptyline was 2.68 (0.80–8.97) P 0.10 and duloxetine 0.82 (0.17–3.85) P 0.81. Patients taking low-dose naltrexone reported improvement in fatigue and pain, patients taking amitriptyline and duloxetine reported improvement in fatigue, and patients receiving physical therapy reported improvement in dyspnea and fatigue. An interaction between physical therapy and medications was found (P = 0.04). Biomarker changes were nonsignificant (P > 0.05). Harms were not reported, and the paper did not report study withdrawals. The authors state that the sample size for their analysis was small, which limits the ability to do individual comparisons, and note the retrospective design, incomplete data for inflammatory markers, absence of a no-intervention group, and likely confounding by indication.

  3. Patient-reported treatment outcomes in ME/CFS and long COVID.2025 · no comparison group · 5,451 in the study · 3,925 with outcome data
  4. Longitudinal Progression of Patients with Long COVID Treated in a Post-COVID Clinic: A Cross-Sectional Survey.2024 · no comparison group · 852 in the study · 536 with outcome data
    Summary

    This cross-sectional follow-up survey asked patients with long COVID treated at a US quaternary care clinic to assess treatment response and recovery after the clinic visit. Of 852 patients identified, 536 completed the survey; mean time from infection to survey was 23.2 ± 6.4 months. Patients reported a range of interventions, medications, and supplements; treatment duration was not reported. There was no comparison group. Patients rated symptom severity and overall functioning from 1 to 10 for baseline recall and at follow-up, and rated how helpful treatments were. Median overall functioning improved from 8 (6, 9) to 5 (3, 8), fatigue from 8 (7, 10) to 6 (3, 8), and brain fog from 8 (6, 9) to 5 (3, 8), all P < .001. Only 4.5% (24/536) were classified as recovered completely. A minority reported worsening overall function; similar changes were seen for fatigue, myalgia, and orthostasis, but counts and withdrawals due to harms were not reported. Helpfulness ratings included low-dose naltrexone 45/77 (58%), vagal nerve stimulation 18/34 (53%), and fisetin 28/44 (64%).

  5. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19.2023 · no comparison group · 59 in the study
    Summary

    This retrospective review examined low-dose naltrexone (LDN) in 59 patients with Post-Acute Sequelae of SARS-CoV-2 (PASC) at the Stanford PASC clinic, from 468 adult patients. Patients received LDN off-label as oral dose titration from 0.5 mg daily to 6.0 mg daily; the median number of days on LDN was 143 days [IQR 77–255]. The study had no comparison group, placebo control, or randomization. Questionnaires measured symptoms, symptom severity, and functional status. The authors report a significant improvement in the total number of symptoms, severity in a subset of symptoms (fatigue, post-exertional malaise, unrefreshing sleep, and abnormal sleep pattern), and FSS among patients taking LDN. A sum composite score showed LDN improvement in 32 (54.2%) and worsening in 19 (32.2%) of the selected symptoms. There were no correlations between LDN dose and scored responses to the selected symptoms (correlation coefficient: headache 0.18, fatigue 0.10, brain fog 0.07, unrefreshing sleep 0.13, abnormal sleep pattern 0.13, post-exertional malaise 0.13, and lightheadedness 0). Comparing patients with symptoms for <365 days (28 patients, 47.5%) and ≥365 days (31 patients, 52.5%), there was no statistical difference regarding days on LDN, number of symptoms, changes in the number of symptoms, or improvement in selected symptoms. LDN was well tolerated, and no serious AEs were reported. Limitations included the retrospective, single-center design without placebo control or randomization, incomplete symptom survey data on follow-up, and no assessment of other medications and supplements.

  6. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study.2022 · no comparison group · 52 in the study · 38 started · 36 with outcome data
    Summary

    This prospective single-centre interventional pre-post cohort study enrolled 52 patients with Post COVID-19 Syndrome (PCS) from a Post COVID clinic at Mater Misericordiae University Hospital between June and November 2020. After initial enrolment, 38 patients commenced LDN; 36 completed a follow-up questionnaire at a median 63 days (IQR 56–84). LDN was given as 1 mg once daily for one month, then increased by 1 mg monthly to a maximum of 3 mg, over a two-three month period. No control arm was used; only pre and post analysis was done. The study measured seven Likert components and reported symptoms, and reviewed adverse events. Improvement was seen in 6 of 7 parameters: recovery from COVID-19, limitation in activities of daily living, energy levels, pain levels, levels of concentration and sleep disturbance. Mood was not significantly changed (p = 0.054). Significant symptom reductions were reported for low mood (p = .003), personality change (p = .001), joint pain (p = .008), chest pain/tightness (p = .047) and cough (p = .016). Adverse events in two patients (diarrhoea and fatigue in both) resulted in discontinuation prior to the second questionnaire; three additional patients were lost to follow and it is unknown if they took LDN. The authors state limitations including single centre, small sample size, no control arm, possible placebo or natural improvement, self-report only, and short duration.

  7. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)2019 · no comparison group · 218 in the study · 201 with outcome data
    Summary

    This retrospective open-label study examined low-dose naltrexone (LDN, 3.0–4.5 mg/day) in 218 patients with ME/CFS at a private Unesta Sleep and Breathing Clinic, with records from 2010–2014. LDN was started at 1.5 mg in the morning for one week, then 3.0 mg daily, with an allowed increase to 4.5 mg after six weeks. Follow-up data were available for 201 patients; average follow-up was 1.7 years (range 0.1–6.8 years). There was no comparison group. Treatment response was based on patients’ spontaneous reports; all 218 patients were the denominator. Any treatment response was reported by 73.9% (161/218), while 18.3% did not report any response. 13.8% discontinued LDN for lack of effectiveness after an average of 5.9 months, and 4.6% stopped because adverse symptoms forced discontinuation before response could be assessed (after an average of 1 month [1–57 days]). Adverse symptoms were reported by 54.2%, and 45.8% reported none; symptoms were mostly mild and temporary. Insomnia and nausea were the most common adverse symptoms (15.3% each). Serious adverse effects were not reported. 15 patients (7.5%) discontinued LDN due to adverse symptoms; nausea was the most common reason (5 patients, 2.5%), and increased anxiety was the reason in two patients (1.0%). The text also states 7.3% discontinued because of adverse symptoms.

  8. Utilising Continuous HRV Biofeedback Data for Autonomic Nervous System Regulation in ME/CFS Relapse Management2026 · case report · 1 in the study · preprint
    Summary

    This case report describes one patient with ME/CFS for relapse management in standard client sessions who used continuous heart rate variability (C-HRV) biofeedback with an ECG-grade Firstbeat Life device, health coaching and HRV specialist interpretation for an 11-week intervention, alongside pacing, sleep optimisation, task modification and autonomic regulation strategies. There was no comparison group. The paper reports within-patient changes from baseline to 11 weeks: baseline HRV (RMSSD) rose from 24 ms to 33 ms (+37.5%); Sleep Quality Score from 37/100 to 56/100 (+51.4%); Stress and Recovery Balance Score from 23/100 to 48/100 (+108.7%); and Subjective Wellbeing from 24% to 34% (+41.7%). On the Firstbeat Wellbeing survey, 'I feel that I sleep enough' was 40% at Week 1 and 80% at Week 11 (difference 40); 'I don't feel stressed' was 80% and 80% (0); 'My days include breaks and time for recovery' 80% and 100% (20); 'I feel alert and energetic most of the time' 20% and 40% (40); 'I feel well at the moment' 20% and 40% (60). Harms reported included a sharp drop in overall HRV and near-total absence of nocturnal PNS recovery during a 10-day low dose naltrexone trial, and a complete lack of PNS recovery during sleep on three separate palmitoylethanolamide trials; a severe immune flare occurred immediately after the 11-week intervention. Withdrawals for harms were not reported. The authors state the findings are from a single case (N=1) and may not be representative.

  9. Stellate Ganglion Block for Headache Pain and Cognitive Impairment Associated With Long COVID Persisting Over 12 Months: A Case Report.2025 · case report · 2 in the study
    Summary

    This case report described 2 middle-aged female patients with long COVID (PASC) persisting over 12 months. Both presented to the authors’ practice and were selected as candidates for right-sided stellate ganglion block (SGB); each received 2 SGBs. Case 1 received 6 mL 0.25% bupivacaine + 12 mg betamethasone, then a repeat with 3 mL 0.5%. Case 2 received 3 mL 0.5% bupivacaine. There was no comparison group; outcomes were reported before versus after treatment. Measured outcomes included VAS pain, BPI interference with daily activities, a Visible app overall score, patient-reported pain relief, cognitive function, fatigue, and physical activity. Case 1 reported 40% pain relief following SGB and > 50% after the repeat; at the 2-week follow-up after the second block, migraine pain had recurred and was as severe as before the SGBs. BPI Enjoyment of Life improved by 50%. Case 2 endorsed immediate > 50% pain relief and later > 50% after a repeat SGB; Table 1 showed VAS 6 at baseline and 0 at the 1-week follow-up after the second SGB. Both patients had improvements in cognitive function and fatigue, and increased physical abilities. No complications occurred, and all procedures were tolerated well. The authors state limitations including a small sample, non-identical PASC symptomologies, and no cognitive testing.

  10. Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series.2025 · case report · 13 in the study
    Summary

    This patient-led case series documented the impact of extended-course oral nirmatrelvir/ritonavir in 13 individuals with established Long COVID. Participants came from public forums led by and for people with Long COVID or heard about the project by word-of-mouth. They took courses >5 days (range: 7.5–30 days): 11 outside the context of an acute infection (Cases 1–11) and 2 within an acute reinfection (Cases 12–13). There was no comparison group; participants reported symptoms and health experiences before, during, and after treatment. Some outside-acute participants experienced a meaningful reduction in symptoms, although not all benefits persist; others experienced no effect. The discussion states only 5 of the 13 cases experienced sustained improvement. Individual reports included no change, temporary improvement, return to pre-treatment baseline, and recurrence after stopping. One participant stopped early due to intense stomach pain. Reported harms included severe constipation and a severe MCAS flare, a severe “crash,” insomnia and taste-related side effects, dysgeusia, severe stomach pain with discontinuation, itchiness and tingling, dizziness and shakiness, and a PEM crash. For the two participants treated during acute reinfection, both report eventually returning to their pre-re-infection baseline. The authors list limitations: only 13 individuals who may or may not be representative; patient-reported experiences subject to recall or fatigue bias; and substantial heterogeneity in ages, symptoms, and treatment lengths.

  11. HERV Dysregulation in a Case of Myalgic Encephalomyelitis and Multiple Sclerosis Responsive to Rituximab.2025 · case report
    Summary

    This case report describes a single male patient in his 30s with a co-diagnosis of ME/CFS and MS, followed longitudinally. After a new MS relapse with radiological inflammation, he received rituximab at 1 g on days 1 and 15 of the first month, then nine monthly doses of 1 g adjusted by B-cell repopulation, a 9-month treatment regime. There was no comparison group; outcomes were before-versus-after observations in this patient. The report states a significant improvement in fatigue after the third dose, enabling increased mobility and participation in daily activities such as walking and dining out. On the Bell scale for severity assessment, the patient changed from a level of 10 to 20. After treatment he could leave the house 2–3 times a week and take gentle walks for an hour, and he reported a migraine once a month. The authors report he stayed in remission for at least 3 years after treatment. Harms of rituximab were not reported. The authors note limitations including sub-optimal frequency of MRI to monitor lesion progression and of HERV reassessment after rituximab, and the limited external validity of single study cases.

  12. Clinically Meaningful Improvements in Long COVID Symptoms Following Ketogenic Metabolic Therapy Combined with Lifestyle Interventions-A Clinical Case Report and Review of the Literature.2025 · case report · 1 in the study
    Summary

    This case report describes one patient with Long COVID, POTS and ME/CFS at the OHSU Long COVID Clinic who enrolled in a community-based 12-week educational program. The program combined a ketogenic diet (low-carbohydrate and moderate-protein intake) with daily activities to entrain circadian rhythm, mindfulness-based strategies, and group health coaching; the patient also received thiamine 2000 mg/day and magnesium 3000 mg. No comparison group was reported. Clinical improvements were identified in five of the seven patient-reported measures across dysautonomia, shortness of breath, migraine disability, fatigue, and physical function. Within the first two weeks, chronic hypotension resolved and IV saline therapy was discontinued; she reported increased energy coinciding with ketosis. By the second month, sound and light sensitivity resolved, menstrual cycle normalized to 25 - 29 days, and headaches reduced from 4 - 5 times per week to once or twice a month. PEM after moderate exertion continued, while flushing episodes were diminished. Over 12 weeks, she lost 15% of body weight and BMI changed from 23 to 20 kg/m2; by month seven she worked cognitively 5 - 6 hours per day and exercised 20 minutes daily without triggering PEM, with BMI stabilizing at 21 kg/m. The patient did not report experiencing possible adverse reactions to KMT or vitamin supplementation. The authors state that whether observed benefits are attributed to the interventions or external factors such as placebo effect or natural disease progression cannot be determined, that the most impactful component is difficult to determine, and that results cannot be generalized.

  13. Use of Neuromodulation to Treat Post-COVID Neuropathic Pain: A Case Report.2024 · case report · 1 in the study
    Summary

    This case report describes one 27-year-old man with bilateral upper-extremity neuropathic pain that began with a severe COVID-19 infection about 2 years before presentation. There was no comparison group; reports are before and after treatment in this one patient. He had occupational therapy and trials of amlodipine, sildenafil, gabapentin, duloxetine, and low-dos naltrexone 4.5 mg daily, and a stellate ganglion block, which he said gave no noticeable benefit. He then received a Nevro device with cervical lead placement. A single lead trial with the tip at the C2/C3 interspace gave excellent relief, with a >70% decrease in baseline pain, improved functionality, and increased ability to participate in physical therapy. At implant, two leads were placed, one at C2/C3 and one staggered at C3. More than 6 months after surgery, he reported a 50% improvement in baseline pain and improved functionality, including lifting weights and repetitive motions; he recovered more quickly from pain flares and was quite pleased with the device. Gabapentin seemed most helpful, but he had dosis-limiting side effects, including lethargy. No harms were reported for the device. The authors state limits of case reports: lack of generalisability, inability to establish cause and effect, retrospective design, and potential for overinterpretation.

  14. Sphenopalatine Ganglion Block for Postacute Sequelae SARS-CoV-2 Infection Headaches: A Case Report and Review of the Literature.2023 · case report · 1 in the study
    Summary

    This case report describes 1 patient in her 50s with postacute sequelae SARS-CoV-2 infection (PASC), or Long COVID, who was referred from the PASC clinic to the interventional pain clinic for persistent symptoms including headaches. There was no comparison group and no randomisation. The experimental treatment was a sphenopalatine ganglion block (SPGB) via an infrazygomatic approach, using a 2 mL solution consisting of 1mL of 10 mg/mL dexamethasone and 1 mL of 0.5% bupivacaine; the right side was treated first and then the left side. Background treatments included right and left stellate ganglion blocks, which temporarily relieved most symptoms for 2 weeks and completely resolved the anosmia and ageusia. After the right-sided SPGB, the patient reported more than an 80% improvement in headaches, blurry vision, and eye pain on the right, and significant improvement in sinus congestion, concentration, and short-term memory; the left-sided SPGB resulted in similar relief. The abstract reports an 80% improvement in symptoms after bilateral SPGB. To date, the patient still has significant relief with no refractory symptoms. Conservative therapies had minimal effects; LDN and mesenchymal stem cells gave short-term symptom relief; intravenous nicotinamide adenine dinucleotide therapy gave no alleviation in the last 2 months. No harms were described, and withdrawal from treatment was not reported. The patient was very pleased with the results of the injections into her nose. The authors state the single case is empirical until further case reports or series show similar benefits.

  15. Low-dose naltrexone as a treatment for chronic fatigue syndrome.2020 · case report · 3 in the study
    Summary

    This paper reports a series of three case reports compiled by people with long-term ill-health due to chronic fatigue syndrome and myalgic encephalomyelitis. The three patients took low-dose naltrexone (LDN); treatment doses ranged from 4 to 12 mg. There was no comparison group. The reports describe symptoms, quality of life, functional level, mood and anxiety, and Disability Living Allowance. In case 1, slightly increased energy and reduced food intolerances were reported while taking 4.5 mg/day, but the dose was reduced to 3 mg due to increased headaches; later stepped dose increases coincided with further improvements in energy, mood and pain, and at 9 mg abdominal pain subsided. Case 1 currently has a normal quality of life with no signs of ill health, and Disability Living Allowance stopped 3 years after starting LDN. In case 2, improved sleep and lower pain levels were noticed at about 6 months when on 1 mg/day; pain and sleep issues continued at a lower level, but functional level did not improve. Initially, sleep was disturbed by vivid dreaming. In case 3, an improved sleep pattern and fewer colds were reported; average mood improved from 13 to 7 on the Hospital Anxiety and Depression Scale, and functional level improved from 60%–70% to 80%–90% on a functional activity scale. He had no side effects starting the drug. The authors state limitations including lack of controlling for confounding factors and possible placebo responses.

  16. Overlapping Post-COVID Conditions: A Case of Myalgic Encephalomyelitis and Postural Orthostatic Tachycardia Syndrome Triggered by Sequential Epstein-Barr Virus (EBV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections.2026 · combination: given with other treatments · 1 in the study
    Summary

    This case report followed one patient with ME/CFS and POTS following SARS-CoV-2 infection at the Carlos Prates Health Center in Belo Horizonte, Minas Gerais, Brazil. The patient received pyridostigmine bromide 60 mg every 12 hours, duloxetine hydrochloride 60 mg/day, naltrexone 2 mg/day, bupropion 300 mg/day, palmitoylethanolamide (PEA) 600 mg/day, vitamin C 1 g/day, Omega-3, hydroxyzine hydrochloride 25 mg/day, methylprednisolone 125 mg/day for three days, vitamin B12 1 mg/day, pacing, and physiotherapy. Treatment duration was not reported. Follow-up was at baseline and after one month, three months, six months, and twelve months. There was no comparison group. The paper reports partial and fluctuating responses; partial improvement in fatigue, orthostatic symptoms, and memory, but worsening of hair loss; worsening of symptoms after starting light walks (10 minutes/day); and discontinuation of acupuncture. The number of withdrawals related to harms was not reported. The authors state this single case cannot determine whether the infections acted as sequential triggers and that no objective biomarkers were available to quantify treatment responses.

  17. Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19.2024 · combination: given with other treatments · 36 in the study · 31 with outcome data
  18. White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome2024 · combination: given with other treatments
    Summary

    This case report examined a synergistic off-label treatment (SOT) in ME/CFS. Ten patients expressed interest; two selected participants were excluded, one because they had to stop spironolactone after developing postural orthostatic tachycardia syndrome (POTS), leaving 8 treated patients. They were compared with eight age-gender matched treatment-naïve ME/CFS patients. SOT comprised spironolactone 25 mg/day, colchicine 0.5 mg/day, low dose naltrexone 1.5–4.5 mg/day, and multivitamins, given for more than 6 months; mean time on treatment was 27.75 (10.82) months. Outcomes included HADS, SF-36, CCC-JDC and standing-task measures. Compared with controls, the SOT group showed reduced HADS depression (PBonf = 0.04) and increased SF-36 Mental Health (PBonf = 0.01). Within the SOT group, CCC-JDC scores were lower post-treatment (10.86 ± 4.49) than at baseline (20.25 ± 2.92; PBonf < .001). HADS anxiety did not differ significantly (p = 0.23), and several SF-36 and standing-task measures also showed no significant differences. Diffusion-weighted imaging showed higher fractional anisotropy and lower diffusivity measures in white-matter tracts in the SOT group compared with controls. The authors state limits including case-report design, small sample size, multiple medications, absence of a sham control group, and recruitment from different resources.

  19. Low Dose Naltrexone Prescribing Practices for Children and Adolescents with Long COVID2026 · how it is prescribed, safety only · 62 in the study · preprint
    Summary

    This multicenter, retrospective case series included 62 pediatric and young adult patients (≤25 years) with a clinical diagnosis of long COVID at three pediatric long COVID programs in the United States. Patients were prescribed low-dose naltrexone (LDN); most initiated at 1·5mg and reached a maximum of 4·5mg/day, with gradual dose escalation. Treatment duration was not reported. The study described full clinic populations as a comparator. Outcomes included treatment tolerability and clinical response, dosing practices, treatment continuation or discontinuation, adverse effects, and available patient-reported quality-of-life measures. LDN was generally well tolerated, with 71·0% of patients experiencing no adverse effects. The most common reported side effects were vivid dreams/nightmares (9·7%), difficulty sleeping/insomnia (9·7%), fatigue (6·5%), headaches/migraines (6·5%), and dizziness/lightheadedness (3·2%). During data collection, 41 patients (66·1%) remained on LDN. Sixteen patients (25·8%) discontinued treatment, mainly due to perceived lack of benefit (43·75%), medication side effects (25·0%), and symptom resolution (18·8%); 12·5% had unknown reasons or unreported data. One patient had not yet initiated the medication. Some patients reported no symptom improvement with LDN but experienced worsening symptoms upon discontinuation, leading to therapy re-initiation. The authors state the study was not designed to assess efficacy.

  20. Evaluating the Therapeutic Benefits of Naltrexone in ME/CFS and Long Covid Patients: A Systematic Literature Review (P9-2.002)2026 · systematic review · abstract
    Summary

    This systematic literature review followed PRISMA protocols and searched PubMed with keywords "naltrexone," “long Covid” and "ME/CFS", resulting in 26 studies. The review included 9 studies reporting 1,449 patients with a mean age of 46.4 years: 36 (2.4%) diagnosed with ME/CFS and 1,413 (97.5%) long covid patients; 75.8% were female and 24.2% male. Treatment dose varied from 3–4 mg/day (44%), 4–5 mg/day (44%), and 5–6 mg/day (12%) over an average period of 7 months. No comparison group was reported. The review reports: “Improvement was shown after the allotted times showing decreased fatigue (66%), brain fog (44%), dysautonomia (11%), shortness of breath (11%), sleep (33%), pain (56%), and mood (22%).” It also reports: “Dosage didn’t present a significant change in the symptom management.” Of the 9 studies, “1 study involving ten patients didn’t provide any change to symptom severity.” For harms, “100% of the studies reported minimal patients presenting diarrhea and fatigue”; whether these were followed by stopping or dose change was not reported. The abstract does not state limitations; it says: “further research is imperative for innovative and personalized patient management.”

  21. Effect of low-dose naltrexone for long COVID: a systematic review and meta-analysis.2026 · systematic review
    Summary

    This systematic review and meta-analysis searched through 5 May 2026 and found no randomised controlled trials; four observational pre–post studies from the USA and Ireland (n=155) met inclusion criteria. The review pooled pre–post analyses of LDN for long covid. Pooled analyses showed a moderate effect size favouring LDN for reducing fatigue (Hedges’ g=−0.74; 95% CI −1.11 to −0.37; p<0.001; I2=47.7%), a large effect for pain (Hedges’ g=−0.93; 95% CI −1.29 to −0.57; p<0.001; I2=0%), a moderate effect for brain fog (Hedges’ g=−0.53; 95% CI −1.01 to −0.05; p=0.03; I2=61.8%), a moderate effect for improving sleep quality (Hedges’ g=−0.60; 95% CI −0.91 to −0.30; p=0.0001; I2=9.2%), and a large effect for improving daily functioning (Hedges’ g=−0.93; 95% CI −1.29 to −0.57; p<0.0001; I2=0.0%). Tamariz et al reported fatigue improvement in 13/24 (54.2%), pain in 12/24 (50%), and brain fog in 4/24 (16.7%); Bonilla et al reported an abnormal sleep pattern effect (Hedges’ g=−0.45; 95% CI −0.81 to −0.08; p=0.016). No serious adverse events were reported in the two studies that assessed safety. The authors state the evidence is of low certainty and that all included studies were uncontrolled pre–post designs, limiting causal inference; observed improvements may reflect natural course, regression to the mean or placebo effects, particularly as outcomes were self-reported.

  22. Does low-dose oral naltrexone alleviate symptoms of long COVID? -- A systematic review and meta-analysis2025 · systematic review
    Summary

    This systematic review and meta-analysis examined low-dose naltrexone (LDN) as a treatment for long COVID. The authors searched MEDLINE, Web of Science (Clavirate), Embase, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL) and Cumulative Index in Nursing and Allied Health Literature (CINAHL) using terms for COVID, COVID-19, SARS-COV-2 and naltrexone. Screening identified five eligible articles. Four studies were included, but only two provided comparable data suitable for meta-analysis, resulting in exclusion of two studies from the meta-analysis. The review is registered on PROSPERO (CRD42025630362). Patient consent was not required because the article was based on already published data from available literature. The number and source of participants, treatment dose and duration, comparator, symptom results, side effects and withdrawals are not reported in the abstract. No before-versus-after or between-group results are reported in the abstract. The abstract does not report any worsening or stopping. The authors' conclusion and their stated need for more robust studies are recorded separately.

  23. Candidate treatments for long COVID: a narrative review of expert and patient-driven priorities.2026 · review
    Summary

    This narrative review mapped evidence for 14 long COVID treatments prioritised by clinicians and people with lived experience, with Australian feasibility/access context and searches until January 2025. Six of 14 had long-COVID-specific RCT evidence: exercise (16 RCTs), multicomponent packages (5 RCTs), coenzyme Q10 (2 RCTs), antivirals (1 RCT), vagus nerve stimulation (1 pilot RCT), and monoclonal antibodies (1 small RCT). A moderate-quality RCT of 155 participants found no significant improvement with Paxlovid versus placebo after 15 weeks. A non-randomised antihistamine trial included 14 treated and 13 control patients; after 20 days, 29% of treated patients had complete resolution and all treated patients showed significant improvement in evaluated symptoms including fatigue, brain fog, abdominal disorders, and increased heart rate compared with controls. In a taVNS pilot RCT of 13 participants (active n = 8, sham n = 5), the active group showed significant improvements in fatigue, mood, and cognitive symptoms; no serious adverse events were observed. A nicotine case study involved 4 participants using 7.5 mg per day for 7 days, with reported improvements up to 6 months. A guanfacine case report found eight out of 12 reported improved cognitive abilities; four discontinued therapy, two for unspecified reasons and two due to hypotension and/or dizziness. CoQ10 RCTs did not report benefit. LDN studies reported possible small benefit; a small number experienced headaches and sleep difficulties. The authors state insufficient direct evidence to inform clinical recommendations.

  24. The expanding potential of low-dose naltrexone in clinical practice with a focus on long COVID.2026 · review
    Summary

    This review examined low-dose naltrexone (LDN) for chronic pain, fibromyalgia, and long COVID, with a focus on long COVID and symptoms resembling ME/CFS. It reports long COVID studies with 59, 31, 108, and 36 participants. In the 59-participant retrospective chart review, LDN was associated with a significant reduction in the number of symptoms and FSS scale (P < 0.002). In the 31-participant open-label study, mean total SF-36 score improved from 36.5 at baseline to 24.8 at week 12 (P < 0.0001). In the 108-participant retrospective cohort, self-reported improvement was 67% with naltrexone, 61% with amitriptyline, and 41% with physical therapy. In the 36-participant pre-post cohort, there was a significant reduction in all symptoms (P < 0.05). The review also describes a pre-post study with improvement in post-COVID-19 Functional Status Scale and fatigue-related symptoms, a combined LDN plus nicotinamide adenine dinucleotide study with results favoring increased quality of life and decreased fatigue after 12 weeks, and 58% of participants reporting LDN helpful. In chronic pain studies, it reports no difference in pain severity for LDN vs placebo (P = 0.55) and no difference between naltrexone and amitriptyline (P = 0.21). The most common adverse effects reported are nausea, sleep disturbances, nightmares, and vivid dreams; one case had dizziness and nausea at 4.5 mg/day that resolved. Worsening and discontinuation were not reported. The authors state evidence is limited by study design biases and small sample sizes.

  25. Laaggedoseerde naltrexon Narratief overzicht van de werkingsmechanismen, het klinische bewijs en het mogelijke gebruik bij long COVID2026 · review
    Summary

    This narrative review examined low-dose naltrexone (LDN) for long COVID, with a search on 27 July 2026 in PubMed/MEDLINE, the Cochrane Library and ClinicalTrials.gov. It reviewed small observational, pre-post and retrospective studies rather than a single cohort of its own. In long COVID, O’Kelly reported that after about two months improvements were reported for energy, pain, concentration, sleep, daily activities and global recovery. Tamariz analysed 108 patients and estimated a hazard ratio for improvement of 5.04 with LDN versus physiotherapy alone, with a wide confidence interval of 1.22 to 20.77; fatigue and pain seemed particularly improved. Bonilla reported improvements in fatigue, post-exertional malaise, sleep and some cognitive complaints in a proportion of patients. Isman studied 36 patients for twelve weeks with LDN 4.5 mg/day plus NAD+ and reported improvement in fatigue and some SF-36 dimensions. Byambasuren’s meta-analysis found moderate effect sizes for fatigue, cognitive fog and sleep quality, and larger effect sizes for pain and daily functioning, but no placebo group. Outside long COVID, a Danish trial in 99 women with fibromyalgia using 6 mg/day for twelve weeks found no significant difference in pain, with a between-group difference of −0.34 point on a 0–10 scale. Reported side effects were intense or unusual dreams, insomnia or fragmented sleep, headaches, nausea, abdominal pain, diarrhoea or constipation, dizziness, agitation or irritability, and transient worsening of fatigue. The authors state that LDN may be considered as an individualised off-label symptomatic trial, with caution because certainty is low and robust long-term safety data in long COVID are lacking.

  26. Immunotherapies for postural orthostatic tachycardia syndrome, other common autonomic disorders, and Long COVID: current state and future direction.2025 · review
    Summary

    This narrative review summarizes literature on immunotherapies for POTS, other common autonomic disorders, and Long COVID. The paper states: “ME/CFS has overlapping clinical features with POTS, OCADs, and Long COVID and is therefore relevant to this review.” It reports no overall number of patients; findings are listed under named studies. In a placebo case control study for IVIG (n = 9) in Long COVID, the review lists resolution (6/9) or improvement (3/9) in clinical response (p = 0.001) and a significant clinical response in neuropathic symptoms (9/9) with IVIG compared to no IVIG (3/7; p = 0.02). A prospective cohort of immunoadsorption (n = 20) is described with 70% of participants responders at 4 weeks post-treatment. A placebo-blinded randomized clinical trial of efgartigimod (n = 53) in post-COVID POTS found “No clinically meaningful improvement when compared to placebo for the MaPS score and COMPASS-31.” In O’Kelly et al. (n = 38), the review lists “2 patients discontinued it due to AE”; in Isman et al. (n = 36), approximately half were clinical responders. Listed adverse effects include headache; internal jugular vein thrombosis (n = 1); and nausea, fatigue, dizziness, insomnia, diarrhea, and SOB. The authors state that further research with large, multicenter, randomized controlled trials of longer duration is needed.

  27. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): diagnosis and management.2025 · review
    Summary

    This narrative review searched PubMed, Web of Science, Embase, and the Cochrane Library from inception to August 2025 and included 211 publications on ME/CFS diagnosis, pathophysiology, assessment, and treatment. It summarized pharmacological and non-pharmacological interventions. Reported examples include a double-blind, randomized, placebo-controlled trial of IVIG in 99 CFS patients that found an absence of dose-dependent efficacy; a Phase III rintatolimod study in 208 ME/CFS patients in which 51.2% of a severely debilitated subgroup (n = 21/41) had a ≥ 25% improvement in exercise treadmill test duration; a 12-week trial in 207 ME/CFS patients reporting significant reductions in fatigue with CoQ10 (200 mg) and nicotinamide adenine dinucleotide (20 mg); LDN showing significant improvement in 73.9% of 218 ME/CFS patients; and a pilot study of 55 ME/CFS patients in which oral minocycline produced favorable symptom improvements for 80% of treatment completers. A pooled analysis of 1,298 ME/CFS patients from eight trials associated CBT with significant reductions in fatigue severity and functional impairment. A pragmatic trial in 241 adolescents (aged 8–17) found no significant inter-group difference between GET and activity management for physical function on the Short-Form 36 at 6 months. A systematic review and meta-analysis reported a significant reduction in fatigue (Hedges’ g = -0.52) and an improvement in physical function with pacing compared with no treatment or routine care. Harms included GET-associated symptom exacerbation in a significant proportion of patients, and rintatolimod adverse events may occur. TCM findings should be cautiously interpreted because the available evidence is constrained by methodological limitations.

  28. Therapeutic options for the treatment of post-acute sequelae of COVID-19: a scoping review.2025 · review
    Summary

    This scoping review summarized studies of treatments for post-acute sequelae of COVID-19 (PASC). It included 39 articles identified from PubMed, Embase, and Cochrane library searches between January 1, 2020, and July 22, 2024. Included studies evaluated hyperbaric oxygen, ivermectin, metformin, low dose naltrexone, PEA-LUT, micronutrient supplements, antifibrotic agents, antiviral agents, and SSRIs; some compared with placebo, control groups, physical therapy alone, or no treatment. Findings were reported study by study, without one pooled participant total. Results included improvements in cognitive function, sleep quality, psychiatric symptoms and pain with hyperbaric oxygen; no effect of ivermectin on PASC incidence in the COVID-OUT study; a hazard ratio of 0.59 for metformin among 1126 patients observed for nine months; a hazard ratio of 5.04 for low dose naltrexone compared with physical therapy alone among 108 patients with PASC; and improved TDI scores with umPEA-LUT (21.8 ± 9.4 to 29.7 ± 7.5). In a randomized study (n = 30), nintedanib and pirfenidone improved pulmonary function, 6-minute walk test distances and oxygen saturation over 12 weeks; nintedanib showed greater improvement in 6MWT distance (p = 0.02) and oxygen saturation (p = 0.005), with diarrhea (80%) and nausea/vomiting (66.6%). HBOT: 12 out of 20 patients experienced adverse events, with 31 adverse events reported. Alpha-lipoic acid showed no significant CCCRC score difference (p = 0.63), and NMV-r showed no significant differences in 29 out of 31 post-COVID-19 conditions. The authors state that studies published after the literature search were not included.

  29. Pharmacological Approaches to the Management of Long COVID2025 · review
    Summary

    This review examines pharmacological approaches to Long COVID. It does not report its own enrolled patients, setting, treatment duration, comparison group, or harms. The review describes antivirals including Paxlovid (nirmatrelvir/ritonavir), remdesivir, and molnupiravir; immunomodulatory agents including low-dose naltrexone (LDN); monoclonal antibodies including casirivimab/imdevimab; and other agents including larazotide. For established Long COVID, it states: 'However, trials in established Long COVID patients have shown no significant benefit compared to placebo.' It also states: 'However, treatment of Long COVID patients with a combination of Paxlovid and remdesivir has shown some promising results30.' For LDN, it reports 'showing promise in small cohorts with fatigue and pain in post-acute sequelae of COVID-19 (PASC)33.' For casirivimab/imdevimab, it reports: 'Some studies have shown remission of Long COVID symptoms in a small number of patients, using casirivimab/imdevimab Monoclonal Antibody (mAb) cocktail (REGEN-COV).' For larazotide, it reports: 'Early use has reduced circulating viral antigen and improved symptoms in the pediatric PASC trial38.' The review concludes: 'No single pharmacologic treatment has yet proven successful in large trials, although several immunomodulators and antivirals are under investigation.' It states that most trials remain early-phase or exploratory and that larger stratified studies are needed.

  30. Interventions for Long COVID: A Narrative Review.2025 · review
    Summary

    This narrative review synthesized evidence from 97 studies (n=8260, 103 publications) on interventions for common long COVID symptoms: fatigue, neurocognitive symptoms, anxiety, depression, and sleep issues. The review included randomized and non-randomized studies and compared medications, rehabilitation, behavioral and mind-body programs, supplements, complementary treatments, and COVID-19 vaccination with placebo, usual care, no treatment, or other active comparators. For vortioxetine versus placebo, one RCT (n = 141) reported a significant reduction in depression symptoms (adjMD of −1.52; 95% CI −2.85 to −0.19) and improvement in quality of life (WHO-5, adjMD of 2.36; 95% CI 0.77 to 3.94), with mixed cognitive results. An RCT of “Fit after COVID” CBT (n=114) reported improvement in fatigue (CIS-fatigue: MD −8.8; 95% CI −11.9 to −5.8), cognitive impairment (CIS-concentration: MD −5.1; 95% CI −6.9 to −3.4), and physical function (SF-36-Physical Health: MD 7.1; 95% CI 2.9 to 11.3). Hyperbaric oxygen therapy (n=73) improved fatigue (SF-36 energy subscale, 18.2 vs 6.0, p=0.029) and sleep quality (PSQI, 8.1 vs 9.2, p=0.042) versus sham. Transcranial direct current stimulation (n=47) reduced physical fatigue (MFIS-Physical: p=0.034) but not overall fatigue (MFIS-Total: p=0.184). A COVID-19 vaccine study (n=453) found no statistically significant difference in fatigue, depression, or sleep quality. Adverse events included treatment-related reactions with vortioxetine (26.8% vs. 22.1%), non-serious adverse events with AXA1125 (RR 2.62, 95% CI 1.00 to 6.89), and similar adverse event rates with SIM01 (10% vs. 11%; p=0.63).

  31. A review of post COVID syndrome pathophysiology, clinical presentation and management in children and young people.2025 · review
    Summary

    This review summarises Post Covid Syndrome (PCS) in children and young people, a complex multi-system disorder with a spectrum of presentations. It asks how management strategies address symptoms and their impact on functioning. The review reports no study enrolment, follow-up or analysed numbers for itself, no comparison group and no randomisation. Treatment durations are not reported. It discusses paced activity management, salt, fluids and compression, probiotics, H1 and H2 antihistamines, nirmatrelvir, hyperbaric oxygen, naltrexone and breathing retraining. It cites Xie et al., who reported a reduced risk of PCS in adults with a mean age of 62 years treated with nirmatrelvir in the acute phase. An observational study of 49 adults with PCS treated with histamine receptor antagonists reported clinical improvement in 72%. A study of naltrexone (3-4.5mg/day) in 218 patients with ME/CFS reported improvement in 74%. A double blinded sham controlled randomised trial of adults with a mean age of 48 years reported improved cognitive functioning, fatigue, psychiatric symptoms and pain with hyperbaric oxygen. The review notes that over exertion can cause worsening of symptoms in the subsequent days, that the risk of bleeding is notable, and that blood thinning treatment carries an increased risk of injuries in this age group. It states the literature has limitations and the evidence base for treatment in children and young people remains limited.

  32. Low–dose naltrexone for Long COVID2025 · review
    Summary

    This integrative review asked how low-dose naltrexone affects people living with Long COVID. The author searched CINAHL and MEDLINE and Google Scholar and selected ten articles for analysis. No included study had a comparison group or randomisation; the review describes the evidence as small, non-randomised, and unblinded. The reviewed studies reported symptom outcomes after LDN, chiefly fatigue and pain, with some also reporting sleep disturbances and general functionality. Bonilla et al., O’Kelly et al., and Tamariz et al. reported pain as most improved by LDN. Bonilla et al., Tamariz et al., Isman et al., and Petracek et al. reported fatigue as one of the symptoms most improved. Bonilla et al. also reported fewer symptoms overall and improved general functionality, which Petracek et al. echoed. In Isman et al.’s study of 36 participants, fatigue seemed more improved in females than males; the authors noted the much lower number of males enrolled (11 vs 25 females). O’Kelly et al. found no side effects in 94.7% of participants; one reported diarrhea and another fatigue. In Isman et al., four of 36 participants withdrew due to adverse effects, three in the first few weeks, and side effects were mild and more common at the beginning of treatment. The author states limitations including possible incomplete identification of literature, interpretive bias, and exclusion of non-English articles.

  33. Nutritional Interventions, Nutraceuticals, and Metabolic Therapies for Long COVID and Post-COVID-19 Vaccination Syndrome2025 · review
    Summary

    This REVIEW ARTICLE summarizes nutritional, nutraceutical, and metabolic treatments for long COVID/post-acute COVID-19 syndrome (PACS) and post-COVID-19 vaccination syndrome (PCVS); it reports no own cohort or setting. For low-dose naltrexone (LDN), O’Kelly et al. reported benefits in 52 long COVID patients over a 2–3-month period, including improvement in self-reported activities of daily living, energy, pain, concentration, sleep disturbance, and overall recovery, and decreased coughing, chest tightness, personality changes, low mood, and joint discomfort; pain improved most. In observational research by Glynne et al., 72% of individuals with long COVID who underwent antihistamine treatment showed noticeable but gradual symptom improvement, except dysautonomia. A nonrandomized controlled clinical experiment found 6 weeks of oral anhydrous enol-oxaloacetate (AEO) decreased physical and mental fatigue in ME/CFS and long COVID; ME/CFS patients receiving 500 and 1000 mg twice a day and three times a day improved from 21.7 to 33.3% versus baseline, and long-COVID fatigue improved up to 46.8% over baseline. A randomized controlled clinical trial reported vitamins K2/D3 improved GI and inflammatory markers, the RECOVER long COVID index, and other long COVID symptoms. Among 668 responders with long COVID, between 40 and 70% reported some symptom improvement after nattokinase, serrapeptase, or lumbrokinase; 13 out of 14 long COVID patients in a case series who fasted for an extended period improved. The review notes increased free zinc may negatively affect antibody production and excess zinc is harmful. The authors state additional large-scale controlled studies and future randomized controlled trials are needed.

  34. Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment.2024 · review
    Summary

    This literature review searched EBSCOhost Academic Search Premier, Proquest, Google Scholar, and the Cochrane Library in June 2022 for published treatments for chronic inflammatory response syndrome (CIRS), ME/CFS, and sick building syndrome. No patients were enrolled by the review; no comparison group, randomization, or follow-up duration was reported. The review reports 13 articles comprising 14 studies on CIRS treatment and also reviews CFS treatment studies. Named CIRS study sizes included 8, 13, 28, 14, 21, 156/111, 20, 35/4, 100, and 68/23. The review states the only treatment with documented clinical efficacy was the Shoemaker Protocol, described in 11 of the 13 articles; table entries list cholestyramine and vasoactive intestinal peptide as successful, while Rea’s antigen intradermal treatments had lack of objective data. CFS studies listed sizes including 49, 1518, 1030, 2036, 62, 409, 101, 171, 33, 32/18, 23, and 218; findings included some benefit for aripiprazole in 101 patients, high frequency of response for low-dose naltrexone in 218, and CBT/GET reported beneficial in six studies but noncurative. Reported side effects include constipation from cholestyramine, hyponatremia from desmopressin, and light-headedness from vasoactive intestinal peptides; medication intolerance was a barrier.

  35. Beyond Antivirals: Alternative Therapies for Long COVID.2024 · review
    Summary

    This scoping review mapped evidence on non-antiviral treatments for Long COVID/PASC, searching PubMed between January 2021 and September 2024; 2032 potentially relevant articles were identified and 18 studies met inclusion criteria. The included evidence covered metformin, low-dose naltrexone (LDN), dexamethasone, statins, omega-3 fatty acids, L-arginine plus vitamin C, IVIg, therapeutic apheresis, NAC, CoQ10, guanfacine, and maraviroc plus pravastatin, across randomized trials, observational research, and case series. In the review’s synthesis, metformin was reported with reductions in Long COVID incidence of 42% to 63% in two large phase 3 trials; LDN was reported with a five-fold higher likelihood of improvement compared with physical therapy alone and, in studies, over 50% of participants reported cognitive improvements. Dexamethasone was reported with a 33% reduction in fatigue and median symptom duration of 133 days vs. 271 days; omega-3 findings involved 33,908 patients; L-arginine plus vitamin C was reported with 94.9% reporting absence of fatigue and 74.2% no dyspnea. Therapeutic apheresis was reported with improvement in 70% of 27 patients, IVIg in 70–75% of patients in smaller studies, and NAC in 67% of 12 patients, with a 25% discontinuation rate due to side effects. The authors state limits: heterogeneity across included studies, reliance on observational studies or small-scale trials, limited long-term data, and an evolving condition.

  36. Theory: Treatments for Prolonged ICU Patients May Provide New Therapeutic Avenues for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).2021 · review
    Summary

    This paper is an overview of treatment trials for prolonged intensive care unit (ICU) patients, related to ME/CFS; it reports no study enrollment or analysis numbers for an own cohort. It discusses trials of peripheral hormones and pituitary secretagogues. In fibromyalgia, Lowe et al. reported "significant improvement in clinical symptoms were recorded in T3 phases compared to baseline and placebo phases" with T3 at 75–150 mcg/day. Teitelbaum et al. reported that euthyroid ME/CFS and fibromyalgia patients given T4 (Synthroid) or naturally desiccated thyroid hormone (Armor Thyroid) "in addition to adrenal hormones, vitamins, minerals, and antibiotics—also experienced significant improvements." In prolonged critical illness, van den Berghe et al. reported that GHRH or GHRP-2 "reactivated the pulsatile secretion of GH by the pituitary, and the plasma concentrations of IGF-1 and IGFBP-3 increased"; TRH reactivated pulsatile TSH and increased T4 and T3; reverse T3 also increased. The paper states that "somewhat higher doses of hydrocortisone (25–35 mg per day) lead to a moderate decrease in endogenous adrenocorticotropic hormone (ACTH) and cortisol production in ME/CFS patients." Harms include "a large-scale double-blind randomized control study of rhGH infusions undertaken in 1999 resulted in increased mortality of critically ill patients." The authors state limitations: "ME/CFS and prolonged critical illness are not identical illnesses."

  37. Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment.2021 · lab study · 18 in the study
    Summary

    This study investigated the potential therapeutic effect of low-dose naltrexone (LDN) in ME/CFS. Nine ME/CFS patients taking LDN (3.0–5.0 mg/day for at least 4 weeks) and nine age- and sex-matched healthy controls were recruited from the NCNED patient database; eighteen participants were included. TRPM3 ion channel activity was measured in NK cells with whole-cell patch-clamp, and ME/CFS patients self-reported symptom severity prior to and after taking LDN. The paper reports that ME/CFS patients taking LDN had restored TRPM3-like ionic currents in NK cells, and PregS-evoked currents reached the same level as in healthy controls. On self-report, impaired thought, concentration and cognitive overload improved (p=0.004), as did other immune disturbances (p=0.024). No significant changes were reported for memory consolidation issues (p=0.077), sleep disturbances (p=0.077), muscle pain (p=0.605), joint pain (p=0.730), sore throat (p=0.077), tender lymph nodes (p=0.136), gastrointestinal disturbances (p=0.297), urinary disturbances (p=0.136), POTS (p=0.489), or thermostatic instability (p=0.077). Harms and withdrawals were not reported. The authors state the study supports planning and approval of prospective randomized clinical studies on the role and dose of NTX in treating ME/CFS patients.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime